Skip to main content
Atrás
Watch Compare

Avalo Therapeutics, Inc.

Calidad de datos: 100%
AVTX
Nasdaq Manufacturing Chemicals
$13.66
▼ $0.55 (-3.87%)
Cap. Mercado: 322.91 M
Precio
$14.17
Cap. Mercado
322.91 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Revenue declined -67.67% annually over 5 years
Negative free cash flow of -51.46 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 18.95%

Crecimiento

Revenue Growth (5Y)
-67.67%
Below sector avg (1.82%)
Revenue (1Y)-86.62%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-79.81%
Below sector avg (-53.53%)
ROIC-49.15%
Net Margin-132642.37%
Op. Margin-123601.69%

Seguridad

Debt / Equity
N/A
Current Ratio14.28
Interest CoverageN/A

Valoración

PE (TTM)
-4.13
Below sector avg (-1.48)
P/B Ratio3.53
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1366 pares)
Métrica Acción Mediana del Sector
P/E -4.1 -1.5
P/B 3.5 1.6
ROE % -79.8 -53.5
Net Margin % -132642.4 -41.5
Rev Growth 5Y % -67.7 1.8
D/E — 0.3

Precio Objetivo de Analistas

11 analistas
Buy
Actual
$13.66
+193.5%
Objetivo
$40.09
$24.00
$40.00
$52.00
Pronóstico
P/E Futuro -4.50
EPS Futuro -$3.03
Ingresos Est. 0.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$3.03
-$3.98 – -$1.33
 0.0 6
FY2026 -$3.24
-$3.67 – -$2.41
 0.0 6

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$1.50 -$0.37 +75.3%
Q32025 -$1.64 -$2.19 -33.7%
Q22025 -$1.46 -$1.92 -31.7%
Q12025 -$1.61 -$1.25 +22.1%

ETFs Holding This Stock

AVDV logo AVDV Avantis International Small Cap Value ETF
0.00% weight
AVDS logo AVDS Avantis International Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -86.62% Revenue Growth (3Y) -82.49%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -67.67% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 59,000.0 Net Income (TTM) -78.26 M
ROE -79.81% ROA -62.19%
Gross Margin N/A Operating Margin -123601.69%
Net Margin -132642.37% Free Cash Flow (TTM) -51.46 M
ROIC -49.15% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 14.28
Interest Coverage N/A Asset Turnover 0.00
Working Capital 105.87 M Tangible Book Value 81.05 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4.13 Forward P/E N/A
P/B Ratio 3.53 P/S Ratio 5473.09
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -15.94%
Market Cap 322.91 M Enterprise Value 295.95 M
Per Share
EPS (Diluted TTM) -5.84 Revenue / Share 0.00
FCF / Share -2.26 OCF / Share -2.26
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 65.75%
SBC-Adj. FCF -62.42 M Growth Momentum -18.95

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 59,000.0 441,000.0 1.92 M 18.05 M 5.40 M
Net Income -78.26 M -35.13 M -31.54 M -41.66 M -84.38 M
EPS (Diluted) -5.84 -20.91 -114.00 -4.43 —
Gross Profit — — — — —
Operating Income -72.93 M -68.51 M -27.35 M -37.44 M -82.13 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — 10.30 M — —
D&A 344,000.0 169,000.0 158,000.0 166,000.0 1.66 M
Interest Expense — — — — —
Income Tax 165,000.0 114,000.0 14,000.0 28,000.0 -196,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 116.46 M 150.73 M 20.99 M 33.37 M 80.21 M
Total Liabilities 33.41 M 17.70 M 13.69 M 44.28 M 57.13 M
Shareholders' Equity 83.05 M 133.03 M 7.30 M -10.92 M 23.08 M
Total Debt — — — — —
Cash & Equivalents 15.86 M 134.55 M 7.42 M 13.17 M 54.59 M
Current Assets 105.29 M 138.89 M 8.40 M 16.42 M 61.85 M
Current Liabilities 12.94 M 6.96 M 4.62 M 22.11 M 19.89 M